Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23742733 | 0.86 | MAPT (0.46) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL12388161 | 0.86 | MAPT (0.46) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL12110239 | 0.85 | MAPT (0.56) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL13394511 | 0.85 | MAPT (0.51) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL12435219 | 0.85 | MAPT (0.51) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL24192686 | 0.82 | PDE2A (0.42) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL24191926 | 0.82 | PDE2A (0.42) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL12110242 | 0.81 | CDK1 (0.41) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL14511179 | 0.77 | MAPT (0.68) | MAPTKDM4ETDP1ALDH1A1APEX1 | |
| SCHEMBL13373552 | 0.76 | MAPT (0.43) | MAPTKDM4ETDP1ALDH1A1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2020185695-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | MAPT 3663/4885KDM4E 3466/4885TDP1 2354/4885 |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | MAPT 4226/4885KDM4E 2622/4885TDP1 2632/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | MAPT 3833/4885KDM4E 2704/4885TDP1 3171/4885 |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | MAPT 4344/4885KDM4E 2688/4885TDP1 3087/4885 |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | MAPT 3807/4885KDM4E 2624/4885TDP1 2408/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | MAPT 3807/4885KDM4E 2624/4885TDP1 2408/4885 |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | MAPT 4242/4885KDM4E 2133/4885TDP1 1996/4885 |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | MAPT 4226/4885KDM4E 2622/4885TDP1 2632/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | MAPT 4211/4885KDM4E 2739/4885TDP1 3334/4885 |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | MAPT 4226/4885KDM4E 2622/4885TDP1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.